Taub Institute: Genomics Core
AN NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER

 

Columbia University
Medical Center
Neurological Institute

710 West 168th Street, 3rd floor
(212) 305-1818


bottom bar
top
make an appointment

Clinical Trials

Clinical Trials Currently Recruiting



Risk of Early Onset Alzheimer’s: DIAN-TU. solanezumab & gantenerumab (Wash Univ/Lilly/Roche)
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or with a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Phase 2 and 3. Intravenous or Subcutaneous or Oral (new arm) Medication. Duration: about 24 months. NCT01760005. Autosomal Dominant AD (individuals at-risk or carriers): Normal, MCI, or mild AD. Age 18-80.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Mild Cognitive Impairment/ Alzheimer’s Disease: MISSION AD elenbecestat (E2609) (Eisai Co.)
A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease. Phase 3. Oral Medication. Once Daily. Duration: 24 months.
NCT02956486. Mild Cognitive Impairment due to Alzheimer’s Disease (AD)/Mild Alzheimer’s Disease (AD). MMSE ≥24. Age 50-85.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Amnestic Mild Cognitive Impairment/Alzheimer’s Disease: donepezil (NIA)
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly. Phase 4. Oral Medication. Duration: about 12 months.
NCT01951118. Amnestic Mild Cognitive Impairment (MCI) or Probable Alzheimer’s Disease (AD). MMSE 18-30. Age 55-95.
(Dr. Devanand) Call Evan Chunga 646-774-7202, Jesse Strickler 646-774-8668

Alzheimer’s Disease: lithium (NIA)
Treatment of Psychosis and Agitation in Alzheimer’s Disease. Phase 2. Oral Medication: lithium or placebo. Duration: 12 weeks. NCT02129348. Possible or Probable Alzheimer’s Disease (AD). MMSE 5-26. Age 55-95.
(Dr. Devanand) Call Evan Chunga 646-774-7202, Jesse Strickler 646-774-8668

Alzheimer’s Disease: AVP-786 (Avanir)
Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.
Phase 3. Oral Medication. Duration: 12 weeks. NCT02442778. Probable Alzheimer’s Disease (AD). MMSE 6-26. Age 50-90.
(Dr. Devanand) Call Evan Chunga 646-774-7202, Jesse Strickler 646-774-8668

Healthy Volunteers: Cocoa Flavanols (Mars, Inc.)
Dietary Flavanols and Dentate Gyrus Function. Oral Medication. Duration: about 24 weeks. NCT02312310. Healthy volunteer. Age 50-75.
(Dr. Small) Call Chu Yi Chen 646-774-8952

Progressive Supranuclear Palsy: ABBV-8E12 (AbbVie)
A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy. Phase 2. Intravenous Medication. Every 28 days. Duration: 52 weeks. NCT02985879. Progressive Supranuclear Palsy (PSP). MMSE ≥15. Age 40-99.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Progressive Supranuclear Palsy: BMS-986168 (BMS-012)
Study of BMS -986168 in Patients With Progressive Supranuclear Palsy. Phase 2. Intravenous Medication. Every 4 weeks. Duration: 52 weeks. NCT03068468. Progressive Supranuclear Palsy (PSP). MMSE ≥20. Age 41-86.
(Dr. Honig) Call Katrina Cuasay 212-305-2077, Ruth Tejeda 212-305-7661, Evelyn Dominguez 212-305-2371

Frontotemporal Dementia: lithium
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia Phase 2/3. Oral Medication: lithium or placebo. Duration: 12 Weeks. NCT02862210. Frontotemporal Dementia (FTD). MMSE 5-26. Age 40-85
(Dr. Huey) Call Hannah Silverman (212) 305-1561

Huntington’s Disease: SIGNAL (Vaccinex)
VX15/2503 Treatment for Huntington’s Disease. Phase 2. Intravenous Medication. Duration: 12 or 16 months. NCT0248167. Huntington’s Disease (HD). Age >21. MoCa >23.
(Dr. Marder) Call Paula Wasserman 212-305-4597, Ronda Clouse 212-305-2387

Huntington’s Disease: STAIR (NeuroNEXT)
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease. Phase 2. Oral Medication. Duration: 12 weeks. NCT02507284. Huntington’s Disease (HD). Age >18.
(Dr. Marder) Call Paula Wasserman 212-305-4597, Ronda Clouse 212-305-2387

Observational Studies Currently Recruiting


Mild Cognitive Impairment or Dementia: IDEAS
Imaging Dementia—Evidence for Amyloid Scanning Mild Cognitive Impairment (MCI) or dementia. Age ≥65. NCT02420756.
(Dr. Honig) Call Betina Idnay 212-342-5615

Mild Cognitive Impairment: ADRC Project 1
White Matter and Hippocampal Circuitry Mild Cognitive Impairment (MCI). Duration: 2 visits, 2.5hrs each visit. CDR 0 or 0.5. Age ≥60.
(Dr. Brickman) Call Christiane Hale 646-317-4072

Mild Alzheimer’s Disease/ Mild Cognitive Impairment/Normal Cognition: Inflammation Imaging in AD
Imaging Inflammation in Elders with Different Clinical and Biomarker Profiles of Alzheimer’s Disease Mild Alzheimer’s Disease/Mild Cognitive Impairment/Normal Cognition. Age ≥60. Duration: 5 visits.
(Dr. Kreisl) Call Julia Klein 212-305-9079

Alzheimer’s Disease: Immune Response in AD
Antigen Presentation and Lymphocyte Response in Alzheimer’s Disease Early Alzheimer’s Disease. Age ≥55. MoCa: ≤26 . Duration: 1.5 hrs; 1 visit.
(Dr. Marder) Call Betina Idnay 212-342-5615

Alzheimer’s Disease: DIAN
Dominantly Inherited Alzheimer Network Family members of a person with AD (proband) due to PSEN1, PSEN2, or APP mutations. Duration: Years. Every 1 to 3 years visits. MMSE: any. Age: ≥18; younger but no more than 10 years younger than proband’s AAO.
(Dr. Noble) Call Dolly Reyes-Dumeyer 212-305-5953, Katie Neimeyer 212-305-5909

Alzheimer’s Disease: EFIGA
Genetic Study of Alzheimer’s Disease in Caribbean Hispanics Hispanic families with multiple affected alive-siblings (2+) and an additional individual healthy or not, willing to participate; Duration: 1.5 hours visit (in person). Visits are every 2 years for the duration of the study. MMSE: not needed. Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Angel Piriz 212-305-2309

Alzheimer’s Disease: LOAD
Late Onset Alzheimer’s Disease Any ethnic background families with multiple affected alive-siblings (2+) and an additional individual healthy or not, willing to participate; Children of the affected ≥50yo. Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study. MMSE: not needed. Age Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Pedro Mena 212-305-2309

Alzheimer’s Disease: Naming Study
Assessment and Characterizationof Naming in Older Adults with Epilepsy and PAD Probable Alzheimer’s Disease. MMSE 19-25. Age 56-90. Duration: 90 minutes.
(Dr. Hamberger/Dr. Honig) Call Alicia Williams 212-305-1801

Subjective Cognitive Complaint: SCD Project
Characterizing Subjective Cognitive Decline in Older Adults Subjective Cognitive Complaint. Duration: 1.5hrs. Age ≥65.
(Dr. Cosentino) Call Preeti Sunderaraman 212-342-4190

Dementia with Lewy Bodies: Targeting Lewy Body Pathology
Targeting Lewy Body Specific Pathology Using Biomarkers Dementia with Lewy Bodies. Age ≥65. Duration: 5 years.
(Dr. Marder/Dr. Honig) Call Helen Mejia-Santana 212- 305-9183, Martha Orbe Reilly 212-305-8873

Parkinson’s Disease Dementia/Dementia with Lewy Bodies: Inflammation Imaging in DLB
Imaging Inflammation in Patients with diffuse Lewy body disease Parkinson’s Disease Dementia/Dementia with Lewy Bodies. Age ≥60. Duration: 6 months.
(Dr. Kreisl) Call Julia Klein 212-305-9079

Frontotemporal Lobar Degeneration: ARTFL
Advancing Research and Treatment for Frontotemporal Lobar Degeneration. Observational and a treatment registry. NCT02365922. Individuals and families with a +FH of Frontotemporal Lobar Degeneration (FTLD). Ages 18-85.
(Dr. Huey) Call Masood Manoochehri 212-305-5710

Familial Frontotemporal Dementia: LEFFTDS
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects. Duration: 5 years. NCT02372773. Families with at least one member with known MAPT, PGRN, and C9ORF72 genetic mutation. Age ≥18.
(Dr. Huey) Call Masood Manoochehri 212-305-5710

Frontotemporal Lobar Degeneration: MAPT
Family Study Examination of the earliest symptoms and biomarkers of FTLD MAPT carriers. Members of families with a MAPT mutation. Duration: 5 years.
(Dr. Huey) Call Gayathri Cheran 212-305-1561

Programs Currently Recruiting


Arts and Minds
The Studio Museum in Harlem, New York Historical Society, and El Museo del Barrio
Excluded: persons with depression (only), cognitively normal persons, and patients with dementia in whom agitation is severe and dominating care. Spanish-speakers are welcome. Participants will explore the world of art and culture in these interactive 75-minute programs.
(Dr. Noble) Call Carolyn Halpin-Healy 646-755-3726

A Friend for Rachel
A companionship program
MCI, early AD, early PPA, FTD (if not too behavioral), early DLB (if no hallucinations). Must be mobile and able to go out of home without an aide. Participants will spend a few hours a week with their student friend either exploring NYC or staying near home.
Call Jill Goldman 212-305-7382

bottom bar